The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases
<h3>Purpose:</h3> <p>Previous studies have shown that the PI3K/Akt/mTOR pathway is activated in up to 70% of breast cancer brain metastases, but there are no approved agents for affected patients. GDC-0084 is a brain penetrant, dual PI3K/mTOR inhibitor that has shown promising acti...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 22, 2019
|
| In: |
Clinical cancer research
Year: 2019, Volume: 25, Issue: 11, Pages: 3374-3383 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-18-3049 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1158/1078-0432.CCR-18-3049 Verlag, Volltext: https://clincancerres.aacrjournals.org/content/25/11/3374 
|
| Author Notes: | Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla K. Brastianos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1677188685 | ||
| 003 | DE-627 | ||
| 005 | 20220816225944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190917s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-18-3049 |2 doi | |
| 035 | |a (DE-627)1677188685 | ||
| 035 | |a (DE-599)KXP1677188685 | ||
| 035 | |a (OCoLC)1341243763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ippen, Franziska M. |d 1988- |e VerfasserIn |0 (DE-588)1093609540 |0 (DE-627)853809771 |0 (DE-576)462741524 |4 aut | |
| 245 | 1 | 4 | |a The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases |c Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla K. Brastianos |
| 246 | 3 | 3 | |a The Dual PI3K mTOR Pathway Inhibitor GDC 0084 achieves antitumor activity in PIK3CA Mutant breast cancer brain metastases |
| 264 | 1 | |c February 22, 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.09.2019 | ||
| 520 | |a <h3>Purpose:</h3> <p>Previous studies have shown that the PI3K/Akt/mTOR pathway is activated in up to 70% of breast cancer brain metastases, but there are no approved agents for affected patients. GDC-0084 is a brain penetrant, dual PI3K/mTOR inhibitor that has shown promising activity in a preclinical model of glioblastoma. The aim of this study was to analyze the efficacy of PI3K/mTOR blockade in breast cancer brain metastases models.</p><p><b>Experimental Design:</b> The efficacy of GDC-0084 was evaluated in <i>PIK3CA</i>-mutant and <i>PIK3CA</i> wild-type breast cancer cell lines and the isogenic pairs of <i>PIK3CA</i> wild-type and mutant (H1047R/+) MCF10A cells <i>in vitro</i>. <i>In vitro</i> studies included cell viability and apoptosis assays, cell-cycle analysis, and Western blots. <i>In vivo</i>, the effect of GDC-0084 was investigated in breast cancer brain metastasis xenograft mouse models and assessed by bioluminescent imaging and IHC.</p><h3>Results:</h3> <p><i>In vitro</i>, GDC-0084 considerably decreased cell viability, induced apoptosis, and inhibited phosphorylation of Akt and p70 S6 kinase in a dose-dependent manner in <i>PIK3CA</i>-mutant breast cancer brain metastatic cell lines. In contrast, GDC-0084 led only to growth inhibition in <i>PIK3CA</i> wild-type cell lines <i>in vitro</i>. <i>In vivo</i>, treatment with GDC-0084 markedly inhibited the growth of <i>PIK3CA</i>-mutant, with accompanying signaling changes, and not <i>PIK3CA</i> wild-type brain tumors.</p><h3>Conclusions:</h3> <p>The results of this study suggest that the brain-penetrant PI3K/mTOR targeting GDC-0084 is a promising treatment option for breast cancer brain metastases with dysregulated PI3K/mTOR signaling pathway conferred by activating <i>PIK3CA</i> mutations. A national clinical trial is planned to further investigate the role of this compound in patients with brain metastases.</p> | ||
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 25(2019), 11, Seite 3374-3383 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:11 |g pages:3374-3383 |g extent:11 |a The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-18-3049 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/25/11/3374 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190917 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1093609540 |a Ippen, Franziska M. |m 1093609540:Ippen, Franziska M. |d 910000 |d 911100 |e 910000PI1093609540 |e 911100PI1093609540 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1677188685 |e 351633455X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Franziska M.","display":"Ippen, Franziska M.","role":"aut","family":"Ippen"}],"language":["eng"],"titleAlt":[{"title":"The Dual PI3K mTOR Pathway Inhibitor GDC 0084 achieves antitumor activity in PIK3CA Mutant breast cancer brain metastases"}],"note":["Gesehen am 17.09.2019"],"name":{"displayForm":["Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla K. Brastianos"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"February 22, 2019"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1677188685"],"doi":["10.1158/1078-0432.CCR-18-3049"]},"recId":"1677188685","title":[{"title":"The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases","title_sort":"Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"pubHistory":["1.1995 -"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"origin":[{"publisher":"AACR","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-"}],"disp":"The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastasesClinical cancer research","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"11","issue":"11","year":"2019","pages":"3374-3383","volume":"25","text":"25(2019), 11, Seite 3374-3383"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]}}]} | ||
| SRT | |a IPPENFRANZDUALPI3KMT2220 | ||